Janus Henderson Group
TVTX icon

Janus Henderson Group’s Travere Therapeutics TVTX Stock Holding History

Janus Henderson Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339M Buy
11,419,586
+908,420
+9% +$27.2M 0.16% 139
2025
Q4 		$402M Sell
10,511,166
-88,494
-0.8% -$2.88M 0.18% 123
2025
Q3 		$253M Buy
10,599,660
+1,058,390
+11% +$19.9M 0.12% 165
2025
Q2 		$141M Buy
9,541,270
+2,012,648
+27% +$33.4M 0.07% 220
2025
Q1 		$148M Buy
7,528,622
+3,469,990
+85% +$70.4M 0.08% 211
2024
Q4 		$70.7M Buy
4,058,632
+4,026,819
+12,658% +$71.2M 0.04% 321
2024
Q3 		$445K Hold
31,813
– – ﹤0.01% 2092
2024
Q2 		$261K Sell
31,813
-368
-1% -$2.48K ﹤0.01% 2267
2024
Q1 		$248K Buy
32,181
+1
+0% +$8 ﹤0.01% 2317
2023
Q4 		$289K Sell
32,180
-55
-0.2% -$400 ﹤0.01% 2255
2023
Q3 		$288K Sell
32,235
-6,934,735
-100% -$97.9M ﹤0.01% 2202
2023
Q2 		$107M Buy
6,966,970
+121,157
+2% +$2.2M 0.07% 249
2023
Q1 		$154M Buy
6,845,813
+1,754,528
+34% +$37.3M 0.1% 193
2022
Q4 		$107M Sell
5,091,285
-2,733,685
-35% -$57.9M 0.08% 231
2022
Q3 		$193M Buy
7,824,970
+3,786,339
+94% +$97.8M 0.07% 241
2022
Q2 		$97.9M Sell
4,038,631
-113,416
-3% -$2.85M 0.07% 256
2022
Q1 		$107M Buy
4,152,047
+135,889
+3% +$3.61M 0.05% 302
2021
Q4 		$125M Sell
4,016,158
-6,916
-0.2% -$195K 0.05% 313
2021
Q3 		$97.6M Buy
4,023,074
+117,961
+3% +$2.17M 0.04% 367
2021
Q2 		$57M Sell
3,905,113
-245,443
-6% -$4.84M 0.02% 534
2021
Q1 		$104M Buy
4,150,556
+67,003
+2% +$1.85M 0.05% 362
2020
Q4 		$111M Buy
4,083,553
+426,396
+12% +$9.96M 0.05% 336
2020
Q3 		$67.5M Buy
3,657,157
+745,088
+26% +$14.5M 0.04% 419
2020
Q2 		$59.4M Buy
2,912,069
+2,752,874
+1,729% +$43.8M 0.03% 444
2020
Q1 		$2.32M Buy
+159,195
New +$2.4M ﹤0.01% 984

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Janus Henderson Group's TVTX Position: Q1 2026 in Review

Janus Henderson Group increased its Travere Therapeutics (TVTX) stake by 8.6% in Q1 2026, buying an estimated $27.2M and bringing the position to 11,419,586 shares worth $339M. The position accounts for 0.16% of the portfolio, ranked #139.

Janus Henderson Group first reported a position in TVTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $402M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Janus Henderson Group held 11,419,586 shares of Travere Therapeutics worth $339M as of Q1 2026.
  • Janus Henderson Group bought 908,420 Travere Therapeutics shares in Q1 2026, an estimated $27.2M.
  • Travere Therapeutics made up 0.16% of Janus Henderson Group's portfolio in Q1 2026, its #139 holding.
  • Janus Henderson Group first reported a position in Travere Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Janus Henderson Group's Travere Therapeutics position peaked at $402M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.